|
|
|
|
LEADER |
01982nam a22003375i 4500 |
001 |
000276951 |
005 |
20211019135714.0 |
007 |
cr nn 008mamaa |
008 |
100301s2006 gw | s |||| 0|eng d |
020 |
|
|
|a 9783540297154
|
024 |
7 |
|
|a 10.1007/3-540-29715-4
|2 doi
|
040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
245 |
1 |
0 |
|a Basis and Treatment of Cardiac Arrhythmias /
|c edited by Robert E. Kass, Colleen E. Clancy.
|
250 |
|
|
|a 1st ed. 2006.
|
260 |
# |
# |
|a Berlin, Heidelberg :
|b Springer Berlin Heidelberg :
|b Imprint: Springer,
|c 2006.
|
300 |
|
|
|a IX, 361 p. 66 illus., 4 illus. in color. :
|b online resource.
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
490 |
1 |
|
|a Handbook of Experimental Pharmacology,
|v 171
|
505 |
0 |
|
|a History of Arrhythmias -- Pacemaker Current and Automatic Rhythms: Toward a Molecular Understanding -- Proarrhythmia -- Cardiac Na+ Channels as Therapeutic Targets for Antiarrhythmic Agents -- Structural Determinants of Potassium Channel Blockade and Drug-Induced Arrhythmias -- Sodium Calcium Exchange as a Target for Antiarrhythmic Therapy -- A Role for Calcium/Calmodulin-Dependent Protein Kinase II in Cardiac Disease and Arrhythmia -- AKAPs as Antiarrhythmic Targets? -- ?-Blockers as Antiarrhythmic Agents -- Experimental Therapy of Genetic Arrhythmias: Disease-Specific Pharmacology -- Mutation-Specific Pharmacology of the Long QT Syndrome -- Therapy for the Brugada Syndrome -- Molecular Basis of Isolated Cardiac Conduction Disease -- hERG Trafficking and Pharmacological Rescue of LQTS-2 Mutant Channels.
|
650 |
|
0 |
|a Pharmacology.
|
650 |
|
0 |
|a Cardiology.
|
650 |
|
0 |
|a Human physiology.
|
650 |
1 |
4 |
|a Pharmacology/Toxicology.
|
650 |
2 |
4 |
|a Cardiology.
|
650 |
2 |
4 |
|a Human Physiology.
|
700 |
1 |
|
|a Kass, Robert E.
|e editor.
|
700 |
1 |
|
|a Clancy, Colleen E.
|e editor.
|
710 |
2 |
|
|a SpringerLink (Online service)
|
773 |
0 |
|
|t Springer eBooks
|